Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    mm398
Show Display Options
Rank Status Study
1 Recruiting Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Conditions: Recurrent or Refractory Solid Tumors;   Ewing Sarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Osteosarcoma
Intervention: Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
2 Recruiting Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
Conditions: Solid Tumors;   ER/PR Positive Breast Cancer;   Triple Negative Breast Cancer;   Metastatic Breast Cancer With Active Brain Metastasis
Intervention: Drug: Ferumoxytol followed by MM-398
3 Completed
Has Results
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: MM-398;   Drug: 5 Fluorouracil;   Drug: Leucovorin
4 Recruiting A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer
Condition: Unresectable Advanced Cancer
Interventions: Drug: MM-398;   Drug: Irinotecan;   Drug: Leucovorin (LV);   Drug: 5-fluorouracile (5-FU);   Drug: bevacizumab
5 Recruiting Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Condition: Pancreatic Cancer
Interventions: Drug: nal-IRI;   Drug: 5 fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: nab-paclitaxel;   Drug: Gemcitabine
6 Recruiting A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: BBI608;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan;   Drug: Fluorouracil;   Drug: MM-398
7 Suspended Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Neuroendocrine Neoplasm;   Progesterone Receptor Negative;   Stage IIB Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Cervical Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Ferumoxytol;   Other: Laboratory Biomarker Analysis;   Drug: Liposomal Irinotecan;   Procedure: Magnetic Resonance Imaging;   Drug: Veliparib
8 Enrolling by invitation Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
Condition: High Grade Glioma
Intervention: Drug: nanoliposomal irinotecan
9 Recruiting Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Biological: BAX2398 + 5-FU/calcium levofolinate;   Drug: 5-FU/calcium levofolinate
10 Recruiting Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: MM-151;   Drug: nal-IRI;   Drug: Leucovorin;   Drug: 5-FU

Study has passed its completion date and status has not been verified in more than two years.